Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Swiss Biotechnology firm Lonza, which purchased the Genentech facility in Vacaville last year, reported an income of 6.6 billion in Swiss francs (CHF) for the year 2024, which converts to about ...

Increased menstrual blood loss can be hard to measure and may detract from a woman’s quality of life, but a range of ...

Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

The menopausal transition may represent an inflection point for worsening of multiple sclerosis (MS) in women.

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.